FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:LUC7L-CPM

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: LUC7L-CPM
FusionPDB ID: 50361
FusionGDB2.0 ID: 50361
HgeneTgene
Gene symbol

LUC7L

CPM

Gene ID

55692

1368

Gene nameLUC7 likecarboxypeptidase M
SynonymsLUC7B1|Luc7|SR+89|hLuc7B1-
Cytomap

16p13.3

12q15

Type of geneprotein-codingprotein-coding
Descriptionputative RNA-binding protein Luc7-like 1putative SR protein LUC7B1sarcoplasmic reticulum protein LUC7B1carboxypeptidase Mrenal carboxypeptidaseurinary carboxypeptidase B
Modification date2020032020200313
UniProtAcc

O95232

Main function of 5'-partner protein: FUNCTION: Binds cAMP regulatory element DNA sequence. May play a role in RNA splicing. {ECO:0000269|PubMed:16462885}.

P14384

Main function of 5'-partner protein: FUNCTION: Specifically removes C-terminal basic residues (Arg or Lys) from peptides and proteins. It is believed to play important roles in the control of peptide hormone and growth factor activity at the cell surface, and in the membrane-localized degradation of extracellular proteins. {ECO:0000269|PubMed:12457462}.
Ensembl transtripts involved in fusion geneENST idsENST00000293872, ENST00000337351, 
ENST00000397780, ENST00000397783, 
ENST00000494366, 
ENST00000549691, 
ENST00000338356, ENST00000546373, 
ENST00000551568, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score19 X 17 X 10=323048 X 16 X 10=7680
# samples 2545
** MAII scorelog2(25/3230*10)=-3.6915341649192
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(45/7680*10)=-4.09310940439148
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: LUC7L [Title/Abstract] AND CPM [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: LUC7L [Title/Abstract] AND CPM [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)LUC7L(270648)-CPM(69265736), # samples:2
Anticipated loss of major functional domain due to fusion event.LUC7L-CPM seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
LUC7L-CPM seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
LUC7L-CPM seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:270648/chr12:69265736)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across LUC7L (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CPM (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000293872LUC7Lchr16270648-ENST00000546373CPMchr1269265736-21203661111439442
ENST00000293872LUC7Lchr16270648-ENST00000551568CPMchr1269265736-67023661111439442
ENST00000293872LUC7Lchr16270648-ENST00000338356CPMchr1269265736-66973661111439442
ENST00000337351LUC7Lchr16270648-ENST00000546373CPMchr1269265736-21333791241452442
ENST00000337351LUC7Lchr16270648-ENST00000551568CPMchr1269265736-67153791241452442
ENST00000337351LUC7Lchr16270648-ENST00000338356CPMchr1269265736-67103791241452442
ENST00000397783LUC7Lchr16270648-ENST00000546373CPMchr1269265736-21333791241452442
ENST00000397783LUC7Lchr16270648-ENST00000551568CPMchr1269265736-67153791241452442
ENST00000397783LUC7Lchr16270648-ENST00000338356CPMchr1269265736-67103791241452442

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000293872ENST00000546373LUC7Lchr16270648-CPMchr1269265736-0.0002276450.99977237
ENST00000293872ENST00000551568LUC7Lchr16270648-CPMchr1269265736-0.0001139080.99988604
ENST00000293872ENST00000338356LUC7Lchr16270648-CPMchr1269265736-0.0001148870.9998851
ENST00000337351ENST00000546373LUC7Lchr16270648-CPMchr1269265736-0.0002286760.9997713
ENST00000337351ENST00000551568LUC7Lchr16270648-CPMchr1269265736-0.0001144080.99988556
ENST00000337351ENST00000338356LUC7Lchr16270648-CPMchr1269265736-0.000115390.9998846
ENST00000397783ENST00000546373LUC7Lchr16270648-CPMchr1269265736-0.0002286760.9997713
ENST00000397783ENST00000551568LUC7Lchr16270648-CPMchr1269265736-0.0001144080.99988556
ENST00000397783ENST00000338356LUC7Lchr16270648-CPMchr1269265736-0.000115390.9998846

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for LUC7L-CPM

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
LUC7Lchr16270648CPMchr126926573636685IASKERDLFFELDTVGRELLLHLIDY
LUC7Lchr16270648CPMchr126926573637985IASKERDLFFELDTVGRELLLHLIDY

Top

Potential FusionNeoAntigen Information of LUC7L-CPM in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
LUC7L-CPM_270648_69265736.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
LUC7L-CPMchr16270648chr1269265736366HLA-A02:19ELDTVGREL0.22820.56541019
LUC7L-CPMchr16270648chr1269265736366HLA-B39:13FELDTVGREL0.97160.9607919
LUC7L-CPMchr16270648chr1269265736366HLA-B44:05FELDTVGREL0.84330.5383919
LUC7L-CPMchr16270648chr1269265736366HLA-C05:09ELDTVGREL10.9451019
LUC7L-CPMchr16270648chr1269265736366HLA-C04:10ELDTVGREL0.99990.80431019
LUC7L-CPMchr16270648chr1269265736366HLA-C08:15ELDTVGREL0.99990.96131019
LUC7L-CPMchr16270648chr1269265736366HLA-C04:07ELDTVGREL0.99990.82981019
LUC7L-CPMchr16270648chr1269265736366HLA-C08:04ELDTVGREL0.97420.95731019
LUC7L-CPMchr16270648chr1269265736366HLA-C08:13ELDTVGREL0.97420.95731019
LUC7L-CPMchr16270648chr1269265736366HLA-C04:06ELDTVGREL0.9420.92511019
LUC7L-CPMchr16270648chr1269265736366HLA-C08:03ELDTVGREL0.8620.9731019
LUC7L-CPMchr16270648chr1269265736366HLA-C04:14ELDTVGREL0.79020.7941019
LUC7L-CPMchr16270648chr1269265736366HLA-A02:07ELDTVGREL0.53730.60151019
LUC7L-CPMchr16270648chr1269265736366HLA-C05:09FELDTVGREL0.99970.9865919
LUC7L-CPMchr16270648chr1269265736366HLA-C08:15FELDTVGREL0.99930.9882919
LUC7L-CPMchr16270648chr1269265736366HLA-B40:03FELDTVGREL0.99830.5574919
LUC7L-CPMchr16270648chr1269265736366HLA-B39:08FELDTVGREL0.98780.9645919
LUC7L-CPMchr16270648chr1269265736366HLA-A02:07FELDTVGREL0.96840.6976919
LUC7L-CPMchr16270648chr1269265736366HLA-B44:10FELDTVGREL0.93950.6069919
LUC7L-CPMchr16270648chr1269265736366HLA-C04:07FFELDTVGREL10.9039819
LUC7L-CPMchr16270648chr1269265736366HLA-C05:09FFELDTVGREL10.9886819
LUC7L-CPMchr16270648chr1269265736366HLA-C04:10FFELDTVGREL10.9048819
LUC7L-CPMchr16270648chr1269265736366HLA-C08:15FFELDTVGREL10.9898819
LUC7L-CPMchr16270648chr1269265736366HLA-C04:14FFELDTVGREL0.9990.8858819
LUC7L-CPMchr16270648chr1269265736366HLA-A02:07FFELDTVGREL0.95970.7463819
LUC7L-CPMchr16270648chr1269265736366HLA-C05:01ELDTVGREL10.9451019
LUC7L-CPMchr16270648chr1269265736366HLA-C04:03ELDTVGREL10.87561019
LUC7L-CPMchr16270648chr1269265736366HLA-C08:02ELDTVGREL0.99990.96131019
LUC7L-CPMchr16270648chr1269265736366HLA-C01:03ELDTVGREL0.99990.92961019
LUC7L-CPMchr16270648chr1269265736366HLA-C18:01ELDTVGREL0.99990.83171019
LUC7L-CPMchr16270648chr1269265736366HLA-C04:01ELDTVGREL0.99990.82981019
LUC7L-CPMchr16270648chr1269265736366HLA-A25:01DTVGRELLL0.99740.91131221
LUC7L-CPMchr16270648chr1269265736366HLA-C04:04ELDTVGREL0.91790.91151019
LUC7L-CPMchr16270648chr1269265736366HLA-C08:01ELDTVGREL0.8620.9731019
LUC7L-CPMchr16270648chr1269265736366HLA-C03:06ELDTVGREL0.85810.97741019
LUC7L-CPMchr16270648chr1269265736366HLA-C07:04ELDTVGREL0.76350.88951019
LUC7L-CPMchr16270648chr1269265736366HLA-B08:12ELDTVGREL0.43120.84651019
LUC7L-CPMchr16270648chr1269265736366HLA-B07:13ELDTVGREL0.32530.72411019
LUC7L-CPMchr16270648chr1269265736366HLA-C05:01FELDTVGREL0.99970.9865919
LUC7L-CPMchr16270648chr1269265736366HLA-C04:03FELDTVGREL0.99960.9331919
LUC7L-CPMchr16270648chr1269265736366HLA-C08:02FELDTVGREL0.99930.9882919
LUC7L-CPMchr16270648chr1269265736366HLA-B40:04FELDTVGREL0.99870.7448919
LUC7L-CPMchr16270648chr1269265736366HLA-B39:02FELDTVGREL0.98310.9611919
LUC7L-CPMchr16270648chr1269265736366HLA-B18:11FELDTVGREL0.97560.9249919
LUC7L-CPMchr16270648chr1269265736366HLA-B41:03FELDTVGREL0.86280.8483919
LUC7L-CPMchr16270648chr1269265736366HLA-C05:01FFELDTVGREL10.9886819
LUC7L-CPMchr16270648chr1269265736366HLA-C04:03FFELDTVGREL10.9157819
LUC7L-CPMchr16270648chr1269265736366HLA-C08:02FFELDTVGREL10.9898819
LUC7L-CPMchr16270648chr1269265736366HLA-C04:01FFELDTVGREL10.9039819
LUC7L-CPMchr16270648chr1269265736366HLA-C18:01FFELDTVGREL10.8847819
LUC7L-CPMchr16270648chr1269265736366HLA-B40:04FELDTVGRELL0.99990.7945920
LUC7L-CPMchr16270648chr1269265736366HLA-C04:04FFELDTVGREL0.99850.9284819

Top

Potential FusionNeoAntigen Information of LUC7L-CPM in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of LUC7L-CPM

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1208DLFFELDTVGRELLLUC7LCPMchr16270648chr1269265736366

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of LUC7L-CPM

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1208DLFFELDTVGRELL-7.15543-7.26883
HLA-B14:023BVN1208DLFFELDTVGRELL-4.77435-5.80965
HLA-B52:013W391208DLFFELDTVGRELL-6.80875-6.92215
HLA-B52:013W391208DLFFELDTVGRELL-4.20386-5.23916
HLA-A11:014UQ21208DLFFELDTVGRELL-7.5194-8.5547
HLA-A11:014UQ21208DLFFELDTVGRELL-6.9601-7.0735
HLA-A24:025HGA1208DLFFELDTVGRELL-7.52403-7.63743
HLA-A24:025HGA1208DLFFELDTVGRELL-5.82433-6.85963
HLA-B27:056PYJ1208DLFFELDTVGRELL-3.28285-4.31815
HLA-B44:053DX81208DLFFELDTVGRELL-5.91172-6.94702
HLA-B44:053DX81208DLFFELDTVGRELL-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of LUC7L-CPM

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
LUC7L-CPMchr16270648chr12692657361019ELDTVGRELGAATTAGATACTGTTGGGCGGGAGCTG
LUC7L-CPMchr16270648chr12692657361221DTVGRELLLGATACTGTTGGGCGGGAGCTGCTGCTC
LUC7L-CPMchr16270648chr1269265736819FFELDTVGRELTTTTTTGAATTAGATACTGTTGGGCGGGAGCTG
LUC7L-CPMchr16270648chr1269265736919FELDTVGRELTTTGAATTAGATACTGTTGGGCGGGAGCTG
LUC7L-CPMchr16270648chr1269265736920FELDTVGRELLTTTGAATTAGATACTGTTGGGCGGGAGCTGCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of LUC7L-CPM

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
GBMLUC7L-CPMchr16270648ENST00000293872chr1269265736ENST00000338356TCGA-32-1980-01A

Top

Potential target of CAR-T therapy development for LUC7L-CPM

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to LUC7L-CPM

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to LUC7L-CPM

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource